It's legit. This can be easily confirmed with a a text search.
April 23, 2014
Insmed price target raised to $51 from $45 at Piper Jaffray
Piper Jaffray increased its price target on Insmed after meeting with the company's management, as the firm thinks the company's NTM will be approved. The firm keeps an Overweight rating on the stock.
Different firms have different ratings systems. Maybe it's a simple "Overweight/ Neutral/ Underweight" scheme. Or it's possible that the individual stock ratings are influenced by the firm's sector weightings. In other words, if the firm doesn't like the bio-tech sector, overweight might be the strongest rating for any individual stock in that sector. There are a myriad of potential reasons.